OrthoPediatrics Q3 record revenue $54.6M (+37% YoY); raises FY guidance to $202-204M

ORTHOPEDIATRICS CORP

2024-Q3 EPS reported -$0.94 revenue$152,060,000

Revenue $54.6M (+37% YoY); domestic up 45%, international up 12%.
Net loss $7.9M ($0.34/shr) vs $4.6M ($0.20) YoY; $3.2M one-time refinancing expense.
Adjusted EBITDA $4.0M vs $3.6M in Q3 2023; gross margin 73% vs 77%.
Raised FY 2024 revenue guidance to $202-204M from $200-203M; reaffirmed Adj. EBITDA $8-9M.
Helped record >33,000 children (+50% YoY); Trauma & Deformity +31%, Scoliosis +52%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.